Atherosclerosis Drugs Market

Atherosclerosis Drugs Market Size by Drug Class (Anti-Platelet Medications, Fibric Acid and Omega-3 Fatty Acid Derivatives, Angiotensin-Covering Enzyme (ACE) Inhibitors, Diuretics, Cholesterol Lowering Medications, Beta Blockers, Calcium Channel Blockers, and Others), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, and Others), Global Industry Analysis, Share, Growth, Trends, and Forecast 2022 to 2030

Base Year: 2021 Historical Data: 2019-20
  • Report ID: TBI-12998
  • Published Date: Oct, 2022
  • Pages: 236
  • Category: Healthcare
  • Format: PDF
Buy @ $4700.00 Request Sample PDF

The global atherosclerosis drugs market is expected to grow from USD 45.55 billion in 2022 to USD 55.19 billion by 2030, at a CAGR of 2.43% during the forecast period 2022-2030. The North American region is expected to dominate the market in 2022.

Market Introduction:

Atherosclerosis is a disease associated with the arteries of the human body. Arteries carry oxygen-rich blood from the heart to the rest of the body. The increase in fat or cholesterol level in the bloodstream restricts blood flow. It thickens the arteries and hardens them. The increasing concentration of fat or cholesterol in the bloodstream leads to plaque formation in and around the artery walls. The plaque builds gradually, and the condition is diagnosed only when the plaque obstructs blood flow or ruptures the artery wall. The increased fat or cholesterol is associated with a poor and unhealthy diet without physical exercise. Atherosclerosis leads to several cardiovascular diseases, which are fatal in nature. It is also associated with hypertension. Atherosclerosis is treated with self-care, medications, or surgical interventions. Atherosclerosis drugs are a form of medicine used to treat the condition. The drugs help reduce the plaque formed in the artery and prevent further plaque formation in the bloodstream. They lower the cholesterol level and control the fat from obstructing the blood flow. They reduce the risk of blood clots and rupture. The drugs improve artery health, significantly reducing cardiovascular disease risk. The research and development in the healthcare sector have led to the production of effective atherosclerosis drugs globally. The scientific breakthroughs in medicine will further the development of the market in the forecast period.

Atherosclerosis Drugs Market Size

Get an overview of this study by requesting a free sample

Recent Development

September 2022 – Microsoft entered the pharmaceutical industry again by agreeing to a five-year deal with Novo Nordisk. According to the news announcement, the cooperation has already achieved progress in two areas: first, it has summarized scientific studies, and second, it has studied atherosclerosis, a significant complication of diabetes. The second is more closely related to the creation of new drugs. The team will use AI to create models that can gauge a person's likelihood of developing atherosclerosis or artery plaque formation. The team will also search for fresh atherosclerosis targets and biomarkers.

December 2021 - Leqvio, the first and only small interfering RNA (siRNA) medication to lower low-density lipoprotein cholesterol with two doses a year, following an initial dose and one at three months, was approved by the US Food and Drug Administration (FDA) in December 2021, according to a Novartis announcement.

Market Dynamics:

Drivers:

Increasing geriatric population - According to the World Health Organization, the increasing geriatric population is around 1 billion people aged 60 and above. The number is expected to reach 2 billion or double by 2050. The risk of atherosclerosis increases with age as the cell functions occur at a reduced pace. The risk is further aggravated by bad diet or other co-morbidities. Patients with atherosclerosis are at an increased risk of hypertension, stroke, or other heart conditions. The increasing geriatric population would drive the global atherosclerosis drugs market at a higher risk of atherosclerosis. Atherosclerosis drugs significantly reduce the occurrence of acute diseases like heart attack and stroke that stem due to atherosclerosis.

Lifestyle changes – The increasingly fast-paced lifestyle has deprived the regular diet of average individuals of the necessary nutrients. The rising prevalence of on-the-go snacking associated with the lack of time given the busy lifestyle of the population has increased the intake of fat-based processed foods. The growing intake of highly processed food with a significant proportion of fat increases the risk of atherosclerosis, despite the age group. The unhealthy or poor diet associated with the lifestyle changes of today's population will increase the risk of atherosclerosis, therefore driving the global atherosclerosis drugs market. 

Restraints:

Lack of awarenessAtherosclerosis is an arterial disease that leads to the hardening of arteries, thereby restricting blood movement. Poor diet and lack of exercise are prevalent causes of atherosclerosis. The gradual plaque build-up in the arteries can lead to coronary artery disease, peripheral artery disease, chronic kidney disease, aneurysms, and carotid artery disease, to name a few. The lack of awareness about atherosclerosis's causes, consequences, and treatments will hamper the market's growth. The lack of awareness and messaging about atherosclerosis, its causes, potential impacts, and treatments lead to misdiagnosis and unnecessary surgical procedures.

Opportunities:

Increasing government healthcare expenditure – Atherosclerosis is associated with the heightened risk of cardiovascular diseases such as heart attacks, coronary artery disease, or stroke, which are fatal for the patients. The increasing prevalence of cardiovascular diseases and associated deaths are among the top reasons for global deaths worldwide. The governments are increasing fiscal healthcare expenditure to advance medical care with better technologies, drug therapies, equipment, medical devices, and other infrastructure. They are also encouraging private market players to invest in atherosclerosis drug development by offering a favorable business environment in their respective countries. Therefore, the increasing healthcare expenditure and favorable legislation will provide lucrative opportunities for the growth of the global atherosclerosis market.

Challenges:

Product recalls - The need to improve the healthcare infrastructure after the pandemic has led to robust drug approval mechanisms. However, the urgency to approve and introduce drugs in the market for treating patients has led to hasty drug approvals without proper oversight and a lack of sufficient data supporting the effectiveness of the drugs. The hastiness in approval of drugs has led to product recalls, which hampers the brand image of market players and adversely affects the consumers. Therefore, the increasing product recalls have led to increasing insecurity about the effectiveness of the drugs amongst consumers, which has led to decreased demand. Thereby, product recalls will challenge the growth of the market.

Segmentation analysis:

Regional segmentation analysis:

The regions analyzed for the market include North America, Europe, South America, Asia Pacific, the Middle East, and Africa. The North American region emerged as the largest market for the global atherosclerosis drugs market, with a 41.18% market revenue share in 2022. Significant market players in the region have contributed to developing the regional atherosclerosis drugs market. The strong and well-established healthcare infrastructure, which offers easy access to drug therapies, is also contributing to the regional market's growth. The increasing prevalence of cardiovascular diseases, given the high-cholesterol American diet associated with the multiple fast-food chains across the region, will also drive the demand for atherosclerosis drugs. The increasing obese population, given the poor diet and lack of exercise associated with lifestyle changes, will drive the atherosclerosis drugs market. The increasing diabetic population will also contribute to the growth of the market. The significant geriatric population of the region will also increase the demand for these drugs. The Asia Pacific market is anticipated to grow the fastest during the forecast period. The well-established and ever-expanding pharmaceutical industry of China and India is a significant contributor to the development of the market. The significant older population of China, India, and Japan will also drive the market. The increasing government healthcare expenditure is a positive development for market growth.

North America Region Atherosclerosis Drugs Market Share in 2022 - 41.18%

 

www.thebrainyinsights.com

Check the geographical analysis of this market by requesting a free sample

Drug class segment analysis 

The drug class segment is divided into anti-platelet medications, fibric acid and omega-3 fatty acid derivatives, angiotensin-covering enzyme (ACE) inhibitors, diuretics, cholesterol-lowering medications, beta-blockers, calcium channel blockers, and others. The cholesterol-lowering medications segment dominated the market with a revenue share of around 44% in 2022. The increasing retail, fast food chains globally offering cheap, on-the-go, and accessible meals for the fast-paced world population has led to the intake of foods associated with high cholesterol. High cholesterol levels associated with a poor diet and inactive lifestyle increase the risk of atherosclerosis. Since atherosclerosis is associated with an increased risk of cardiovascular diseases, a leading cause of death globally, governments are focusing on creating awareness about cholesterol-lowering medications to reduce cardiovascular deaths. Governments worldwide are focusing on developing effective cholesterol-lowering medications and implementing initiatives that make them affordable and accessible, which will contribute to the segment's growth. 

Distribution channel segment analysis

The distribution channel segment is divided into hospital pharmacies, online pharmacies, retail pharmacies, and others. The retail pharmacies segment dominated the market with a market share of around 58% in 2022. Expanding retail pharmacies to the most remote places globally will contribute to their growing accessibility and popularity as a distribution channel. Furthermore, retail pharmacies partner as a distributor with multiple brands offering access to several drugs and different brands in one place. The presence of qualified professionals to offer consultation on the medication at these distribution channel sub-segment will also propel the segment's growth.

Some of the Key Market Players:

  • Amgen Inc.
  • AstraZeneca
  • GlaxoSmithKline
  • Hoffmann-La Roche AG
  • Johnson & Johnson Services Inc.
  • Merck & Co. Inc.
  • Novartis Pharmaceuticals Corporation
  • Pfizer
  • Regeneron Pharmaceuticals Inc.
  • Sanofi

Report Description:

Attribute Description
Market Size Revenue (USD Billion)
Market size value in 2022 USD 45.55 Billion
Market size value in 2030 USD 55.19 Billion
CAGR (2022 to 2030) 2.43%
Historical data 2019-2020
Base Year 2021
Forecast 2022-2030
Segments The research segment is based on drug class and distribution channel.
Regional Segments The regions examined for the market are Europe, Asia Pacific, North America, South America, and Middle East & Africa.

Frequesntly Asked Questions

As per The Brainy Insights, the size of the atherosclerosis drugs market was valued at USD 45.55 billion in 2022 to USD 55.19 billion by 2030.

Global atherosclerosis drugs market is growing at a CAGR of 2.43% during the forecast period 2022-2030.

The market's growth will be influenced by the increasing geriatric population.

Lack of awareness could hamper the market growth.

1. Introduction
    1.1. Objectives of the Study
    1.2. Market Definition
    1.3. Research Scope
    1.4. Currency
    1.5. Key Target Audience

2. Research Methodology and Assumptions

3. Executive Summary

4. Premium Insights
    4.1. Porter’s Five Forces Analysis
    4.2. Value Chain Analysis
    4.3. Top Investment Pockets
          4.3.1. Market Attractiveness Analysis By Drug Class
          4.3.2. Market Attractiveness Analysis By Distribution Channel
          4.3.3. Market Attractiveness Analysis By Region
    4.4. Industry Trends

5. Market Dynamics
    5.1. Market Evaluation
    5.2. Drivers
          5.2.1. Increasing geriatric population
          5.2.2. Lifestyle changes
    5.3. Restraints
          5.3.1. Lack of awareness
    5.4. Opportunities
          5.4.1. Increasing government healthcare expenditure
    5.5. Challenges
          5.5.1. Product recalls

6. Global Atherosclerosis Drugs Market Analysis and Forecast, By Drug Class
    6.1. Segment Overview
    6.2. Anti-Platelet Medications
    6.3. Fibric Acid and Omega-3 Fatty Acid Derivatives
    6.4. Angiotensin-Covering Enzyme (ACE) Inhibitors
    6.5. Diuretics
    6.6. Cholesterol Lowering Medications
    6.7. Beta Blockers
    6.8. Calcium Channel Blockers
    6.9. Others

7. Global Atherosclerosis Drugs Market Analysis and Forecast, By Distribution Channel
    7.1. Segment Overview
    7.2. Hospital Pharmacies
    7.3. Online Pharmacies
    7.4. Retail Pharmacies
    7.5. Others

8. Global Atherosclerosis Drugs Market Analysis and Forecast, By Regional Analysis
    8.1. Segment Overview
    8.2. North America
          8.2.1. U.S.
          8.2.2. Canada
          8.2.3. Mexico
    8.3. Europe
          8.3.1. Germany
          8.3.2. France
          8.3.3. U.K.
          8.3.4. Italy
          8.3.5. Spain
    8.4. Asia-Pacific
          8.4.1. Japan
          8.4.2. China
          8.4.3. India
    8.5. South America
          8.5.1. Brazil
    8.6. Middle East and Africa
          8.6.1. UAE
          8.6.2. South Africa

9. Global Atherosclerosis Drugs Market-Competitive Landscape
    9.1. Overview
    9.2. Market Share of Key Players in the Atherosclerosis Drugs Market
          9.2.1. Global Company Market Share
          9.2.2. North America Company Market Share
          9.2.3. Europe Company Market Share
          9.2.4. APAC Company Market Share
    9.3. Competitive Situations and Trends
          9.3.1. Product Launches and Developments
          9.3.2. Partnerships, Collaborations, and Agreements
          9.3.3. Mergers & Acquisitions
          9.3.4. Expansions

10. Company Profiles
    10.1. Amgen Inc.
          10.1.1. Business Overview
          10.1.2. Company Snapshot
          10.1.3. Company Market Share Analysis
          10.1.4. Company Product Portfolio
          10.1.5. Recent Developments
          10.1.6. SWOT Analysis
    10.2. AstraZeneca
          10.2.1. Business Overview
          10.2.2. Company Snapshot
          10.2.3. Company Market Share Analysis
          10.2.4. Company Product Portfolio
          10.2.5. Recent Developments
          10.2.6. SWOT Analysis
    10.3. GlaxoSmithKline
          10.3.1. Business Overview
          10.3.2. Company Snapshot
          10.3.3. Company Market Share Analysis
          10.3.4. Company Product Portfolio
          10.3.5. Recent Developments
          10.3.6. SWOT Analysis
    10.4. Hoffman-La Roche AG
          10.4.1. Business Overview
          10.4.2. Company Snapshot
          10.4.3. Company Market Share Analysis
          10.4.4. Company Product Portfolio
          10.4.5. Recent Developments
          10.4.6. SWOT Analysis
    10.5. Johnson & Johnson Services Inc.
          10.5.1. Business Overview
          10.5.2. Company Snapshot
          10.5.3. Company Market Share Analysis
          10.5.4. Company Product Portfolio
          10.5.5. Recent Developments
          10.5.6. SWOT Analysis
    10.6. Merck & Co. Inc.
          10.6.1. Business Overview
          10.6.2. Company Snapshot
          10.6.3. Company Market Share Analysis
          10.6.4. Company Product Portfolio
          10.6.5. Recent Developments
          10.6.6. SWOT Analysis
    10.7. Novartis Pharmaceuticals Corporation
          10.7.1. Business Overview
          10.7.2. Company Snapshot
          10.7.3. Company Market Share Analysis
          10.7.4. Company Product Portfolio
          10.7.5. Recent Developments
          10.7.6. SWOT Analysis
    10.8. Pfizer
          10.8.1. Business Overview
          10.8.2. Company Snapshot
          10.8.3. Company Market Share Analysis
          10.8.4. Company Product Portfolio
          10.8.5. Recent Developments
          10.8.6. SWOT Analysis
    10.9. Regeneration Pharmaceuticals Inc.
          10.9.1. Business Overview
          10.9.2. Company Snapshot
          10.9.3. Company Market Share Analysis
          10.9.4. Company Product Portfolio
          10.9.5. Recent Developments
          10.9.6. SWOT Analysis
    10.10. Sanofi
          10.10.1. Business Overview
          10.10.2. Company Snapshot
          10.10.3. Company Market Share Analysis
          10.10.4. Company Component Portfolio
          10.10.5. Recent Developments
          10.10.6. SWOT Analysis

List of Table

1. Global Atherosclerosis Drugs Market, By Drug Class, 2019-2030 (USD Billion) 

2. Global Anti-Platelet Medications Atherosclerosis Drugs Market, By Region, 2019-2030 (USD Billion) 

3. Global Fibric Acid and Omega-3 Fatty Acid Derivatives Atherosclerosis Drugs Market, By Region, 2019-2030 (USD Billion) 

4. Global Angiotensin-Covering Enzyme (ACE) Inhibitors Atherosclerosis Drugs Market, By Region, 2019-2030 (USD Billion) 

5. Global Diuretics Atherosclerosis Drugs Market, By Region, 2019-2030 (USD Billion) 

6. Global Cholesterol Lowering Medications Atherosclerosis Drugs Market, By Region, 2019-2030 (USD Billion) 

7. Global Beta Blockers Atherosclerosis Drugs Market, By Region, 2019-2030 (USD Billion) 

8. Global Calcium Channel Blockers Atherosclerosis Drugs Market, By Region, 2019-2030 (USD Billion) 

9. Global Others Atherosclerosis Drugs Market, By Region, 2019-2030 (USD Billion) 

10. Global Atherosclerosis Drugs Market, By Distribution Channel, 2019-2030 (USD Billion) 

11. Global Hospital Pharmacies Atherosclerosis Drugs Market, By Region, 2019-2030 (USD Billion) 

12. Global Online Pharmacies Atherosclerosis Drugs Market, By Region, 2019-2030 (USD Billion) 

13. Global Retail Pharmacies Atherosclerosis Drugs Market, By Region, 2019-2030 (USD Billion) 

14. Global Others Atherosclerosis Drugs Market, By Region, 2019-2030 (USD Billion) 

15. Global Atherosclerosis Drugs Market, By Region, 2019-2030 (USD Billion) 

16. North America Atherosclerosis Drugs Market, By Drug Class, 2019-2030 (USD Billion) 

17. North America Atherosclerosis Drugs Market, By Distribution Channel, 2019-2030 (USD Billion) 

18. U.S. Atherosclerosis Drugs Market, By Drug Class, 2019-2030 (USD Billion) 

19. U.S. Atherosclerosis Drugs Market, By Distribution Channel, 2019-2030 (USD Billion) 

20. Canada Atherosclerosis Drugs Market, By Drug Class, 2019-2030 (USD Billion) 

21. Canada Atherosclerosis Drugs Market, By Distribution Channel, 2019-2030 (USD Billion) 

22. Mexico Atherosclerosis Drugs Market, By Drug Class, 2019-2030 (USD Billion) 

23. Mexico Atherosclerosis Drugs Market, By Distribution Channel, 2019-2030 (USD Billion) 

24. Europe Atherosclerosis Drugs Market, By Drug Class, 2019-2030 (USD Billion) 

25. Europe Atherosclerosis Drugs Market, By Distribution Channel, 2019-2030 (USD Billion) 

26. Germany Atherosclerosis Drugs Market, By Drug Class, 2019-2030 (USD Billion) 

27. Germany Atherosclerosis Drugs Market, By Distribution Channel, 2019-2030 (USD Billion) 

28. France Atherosclerosis Drugs Market, By Drug Class, 2019-2030 (USD Billion) 

29. France Atherosclerosis Drugs Market, By Distribution Channel, 2019-2030 (USD Billion) 

30. U.K. Atherosclerosis Drugs Market, By Drug Class, 2019-2030 (USD Billion) 

31. U.K. Atherosclerosis Drugs Market, By Distribution Channel, 2019-2030 (USD Billion) 

32. Italy Atherosclerosis Drugs Market, By Drug Class, 2019-2030 (USD Billion) 

33. Italy Atherosclerosis Drugs Market, By Distribution Channel, 2019-2030 (USD Billion) 

34. Spain Atherosclerosis Drugs Market, By Drug Class, 2019-2030 (USD Billion) 

35. Spain Atherosclerosis Drugs Market, By Distribution Channel, 2019-2030 (USD Billion) 

36. Asia Pacific Atherosclerosis Drugs Market, By Drug Class, 2019-2030 (USD Billion) 

37. Asia Pacific Atherosclerosis Drugs Market, By Distribution Channel, 2019-2030 (USD Billion) 

38. Japan Atherosclerosis Drugs Market, By Drug Class, 2019-2030 (USD Billion) 

39. Japan Atherosclerosis Drugs Market, By Distribution Channel, 2019-2030 (USD Billion) 

40. China Atherosclerosis Drugs Market, By Drug Class, 2019-2030 (USD Billion) 

41. China Atherosclerosis Drugs Market, By Distribution Channel, 2019-2030 (USD Billion) 

42. India Atherosclerosis Drugs Market, By Drug Class, 2019-2030 (USD Billion) 

43. India Atherosclerosis Drugs Market, By Distribution Channel, 2019-2030 (USD Billion) 

44. South America Atherosclerosis Drugs Market, By Drug Class, 2019-2030 (USD Billion) 

45. South America Atherosclerosis Drugs Market, By Distribution Channel, 2019-2030 (USD Billion) 

46. Brazil Atherosclerosis Drugs Market, By Drug Class, 2019-2030 (USD Billion) 

47. Brazil Atherosclerosis Drugs Market, By Distribution Channel, 2019-2030 (USD Billion) 

48. Middle East and Africa Atherosclerosis Drugs Market, By Drug Class, 2019-2030 (USD Billion) 

49. Middle East and Africa Atherosclerosis Drugs Market, By Distribution Channel, 2019-2030 (USD Billion) 

50. UAE Atherosclerosis Drugs Market, By Drug Class, 2019-2030 (USD Billion) 

51. UAE Atherosclerosis Drugs Market, By Distribution Channel, 2019-2030 (USD Billion) 

52. South Africa Atherosclerosis Drugs Market, By Drug Class, 2019-2030 (USD Billion) 

53. South Africa Atherosclerosis Drugs Market, By Distribution Channel, 2019-2030 (USD Billion) 

List of Figures 

1. Global Atherosclerosis Drugs Market Segmentation

2. Atherosclerosis Drugs Market: Research Methodology

3. Market Size Estimation Methodology: Bottom-Up Approach

4. Market Size Estimation Methodology: Top-Down Approach

5. Data Triangulation

6. Porter’s Five Forces Analysis 

7. Value Chain Analysis 

8. Global Atherosclerosis Drugs Market Attractiveness Analysis By Drug Class

9. Global Atherosclerosis Drugs Market Attractiveness Analysis By Distribution Channel

10. Global Atherosclerosis Drugs Market Attractiveness Analysis By Region

11. Global Atherosclerosis Drugs Market: Dynamics

12. Global Atherosclerosis Drugs Market Share by Drug Class (2022 & 2030)

13. Global Atherosclerosis Drugs Market Share by Distribution Channel (2022 & 2030)

14. Global Atherosclerosis Drugs Market Share by Regions (2022 & 2030)

15. Global Atherosclerosis Drugs Market Share by Company (2021)

This study forecasts revenue at global, regional, and country levels from 2019 to 2030. The Brainy Insights has segmented the atherosclerosis drugs market based on below mentioned segments:

Atherosclerosis Drugs Market by Drug Class:

  • Anti-Platelet Medications
  • Fibric Acid and Omega-3 Fatty Acid Derivatives
  • Angiotensin-Covering Enzyme (ACE) Inhibitors
  • Diuretics
  • Cholesterol Lowering Medications
  • Beta Blockers
  • Calcium Channel Blockers
  • Others

Atherosclerosis Drugs Market by Distribution Channel:

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
  • Others

Atherosclerosis Drugs Market by Region:

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
  • Asia-Pacific
    • Japan
    • China
    • India
  • South America
    • Brazil
  • Middle East and Africa  
    • UAE
    • South Africa

Methodology

Research has its special purpose to undertake marketing efficiently. In this competitive scenario, businesses need information across all industry verticals; the information about customer wants, market demand, competition, industry trends, distribution channels etc. This information needs to be updated regularly because businesses operate in a dynamic environment. Our organization, The Brainy Insights incorporates scientific and systematic research procedures in order to get proper market insights and industry analysis for overall business success. The analysis consists of studying the market from a miniscule level wherein we implement statistical tools which helps us in examining the data with accuracy and precision. 

Our research reports feature both; quantitative and qualitative aspects for any market. Qualitative information for any market research process are fundamental because they reveal the customer needs and wants, usage and consumption for any product/service related to a specific industry. This in turn aids the marketers/investors in knowing certain perceptions of the customers. Qualitative research can enlighten about the different product concepts and designs along with unique service offering that in turn, helps define marketing problems and generate opportunities. On the other hand, quantitative research engages with the data collection process through interviews, e-mail interactions, surveys and pilot studies. Quantitative aspects for the market research are useful to validate the hypotheses generated during qualitative research method, explore empirical patterns in the data with the help of statistical tools, and finally make the market estimations.

The Brainy Insights offers comprehensive research and analysis, based on a wide assortment of factual insights gained through interviews with CXOs and global experts and secondary data from reliable sources. Our analysts and industry specialist assume vital roles in building up statistical tools and analysis models, which are used to analyse the data and arrive at accurate insights with exceedingly informative research discoveries. The data provided by our organization have proven precious to a diverse range of companies, facilitating them to address issues such as determining which products/services are the most appealing, whether or not customers use the product in the manner anticipated, the purchasing intentions of the market and many others.

Our research methodology encompasses an idyllic combination of primary and secondary initiatives. Key phases involved in this process are listed below:

MARKET RESEARCH PROCESS

Data Procurement:

The phase involves the gathering and collecting of market data and its related information with the help of different sources & research procedures.

The data procurement stage involves in data gathering and collecting through various data sources.

This stage involves in extensive research. These data sources includes:

Purchased Database: Purchased databases play a crucial role in estimating the market sizes irrespective of the domain. Our purchased database includes:

  • The organizational databases such as D&B Hoovers, and Bloomberg that helps us to identify the competitive scenario of the key market players/organizations along with the financial information.
  • Industry/Market databases such as Statista, and Factiva provides market/industry insights and deduce certain formulations. 
  • We also have contractual agreements with various reputed data providers and third party vendors who provide information which are not limited to:
    • Import & Export Data
    • Business Trade Information
    • Usage rates of a particular product/service on certain demographics mainly focusing on the unmet prerequisites

Primary Research: The Brainy Insights interacts with leading companies and experts of the concerned domain to develop the analyst team’s market understanding and expertise. It improves and substantiates every single data presented in the market reports. Primary research mainly involves in telephonic interviews, E-mail interactions and face-to-face interviews with the raw material providers, manufacturers/producers, distributors, & independent consultants. The interviews that we conduct provides valuable data on market size and industry growth trends prevailing in the market. Our organization also conducts surveys with the various industry experts in order to gain overall insights of the industry/market. For instance, in healthcare industry we conduct surveys with the pharmacists, doctors, surgeons and nurses in order to gain insights and key information of a medical product/device/equipment which the customers are going to usage. Surveys are conducted in the form of questionnaire designed by our own analyst team. Surveys plays an important role in primary research because surveys helps us to identify the key target audiences of the market. Additionally, surveys helps to identify the key target audience engaged with the market. Our survey team conducts the survey by targeting the key audience, thus gaining insights from them. Based on the perspectives of the customers, this information is utilized to formulate market strategies. Moreover, market surveys helps us to understand the current competitive situation of the industry. To be precise, our survey process typically involve with the 360 analysis of the market. This analytical process begins by identifying the prospective customers for a product or service related to the market/industry to obtain data on how a product/service could fit into customers’ lives.

Secondary Research: The secondary data sources includes information published by the on-profit organizations such as World bank, WHO, company fillings, investor presentations, annual reports, national government documents, statistical databases, blogs, articles, white papers and others. From the annual report, we analyse a company’s revenue to understand the key segment and market share of that organization in a particular region. We analyse the company websites and adopt the product mapping technique which is important for deriving the segment revenue. In the product mapping method, we select and categorize the products offered by the companies catering to domain specific market, deduce the product revenue for each of the companies so as to get overall estimation of the market size. We also source data and analyses trends based on information received from supply side and demand side intermediaries in the value chain. The supply side denotes the data gathered from supplier, distributor, wholesaler and the demand side illustrates the data gathered from the end customers for respective market domain.

The supply side for a domain specific market is analysed by:

  • Estimating and projecting penetration rates through analysing product attributes, availability of internal and external substitutes, followed by pricing analysis of the product.
  • Experiential assessment of year-on-year sales of the product by conducting interviews.

The demand side for the market is estimated through:

  • Evaluating the penetration level and usage rates of the product.
  • Referring to the historical data to determine the growth rate and evaluate the industry trends

In-house Library: Apart from these third-party sources, we have our in-house library of qualitative and quantitative information. Our in-house database includes market data for various industry and domains. These data are updated on regular basis as per the changing market scenario. Our library includes, historic databases, internal audit reports and archives.

Sometimes there are instances where there is no metadata or raw data available for any domain specific market. For those cases, we use our expertise to forecast and estimate the market size in order to generate comprehensive data sets. Our analyst team adopt a robust research technique in order to produce the estimates:

  • Applying demographic along with psychographic segmentation for market evaluation
  • Determining the Micro and Macro-economic indicators for each region 
  • Examining the industry indicators prevailing in the market. 

Data Synthesis: This stage involves the analysis & mapping of all the information obtained from the previous step. It also involves in scrutinizing the data for any discrepancy observed while data gathering related to the market. The data is collected with consideration to the heterogeneity of sources. Robust scientific techniques are in place for synthesizing disparate data sets and provide the essential contextual information that can orient market strategies. The Brainy Insights has extensive experience in data synthesis where the data passes through various stages:

  • Data Screening: Data screening is the process of scrutinising data/information collected from primary research for errors and amending those collected data before data integration method. The screening involves in examining raw data, identifying errors and dealing with missing data. The purpose of the data screening is to ensure data is correctly entered or not. The Brainy Insights employs objective and systematic data screening grades involving repeated cycles of quality checks, screening and suspect analysis.
  • Data Integration: Integrating multiple data streams is necessary to produce research studies that provide in-depth picture to the clients. These data streams come from multiple research studies and our in house database. After screening of the data, our analysts conduct creative integration of data sets, optimizing connections between integrated surveys and syndicated data sources. There are mainly 2 research approaches that we follow in order to integrate our data; top down approach and bottom up approach.

Market Deduction & Formulation: The final stage comprises of assigning data points at appropriate market spaces so as to deduce feasible conclusions. Analyst perspective & subject matter expert based holistic form of market sizing coupled with industry analysis also plays a crucial role in this stage.

This stage involves in finalization of the market size and numbers that we have collected from data integration step. With data interpolation, it is made sure that there is no gap in the market data. Successful trend analysis is done by our analysts using extrapolation techniques, which provide the best possible forecasts for the market.

Data Validation & Market Feedback: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helps us finalize data-points to be used for final calculations.

The Brainy Insights interacts with leading companies and experts of the concerned domain to develop the analyst team’s market understanding and expertise. It improves and substantiates every single data presented in the market reports. The data validation interview and discussion panels are typically composed of the most experienced industry members. The participants include, however, are not limited to:

  • CXOs and VPs of leading companies’ specific to sector
  • Purchasing managers, technical personnel, end-users
  • Key opinion leaders such as investment bankers, and industry consultants

Moreover, we always validate our data and findings through primary respondents from all the major regions we are working on.

Some Facts About The Brainy Insights

50%

Free Customization

300+

Fortune 500 Clients

1

Free Yearly Update On Purchase Of Multi/Corporate License

900+

Companies Served Till Date